Drug Discovery World

NOVEMBER 1, 2022

Researchers say they have successfully used a cell’s natural process for making proteins to ‘slide’ genetic instructions into a cell and produce critical proteins missing from those cells. . Two methods currently used to deliver protein-making packages into cells, ‘mini promoters’ and serotype-mediated gene expression, vary widely.

Gene Expression 52

Gene Expression Gene Protein Packaging 52

XTalks

OCTOBER 21, 2020

The answer may lie in the genetic code of the virus, which scientists at Duke University have found contains several silent mutations that affect protein folding. Related: Study Dispels Claim that COVID-19-Causing Coronavirus is Lab-Engineered. These mutations may thus be “silent” as they do not alter protein structure.

RNA 98

RNA Protein Genome Genomics 98

Roots Analysis

MARCH 16, 2023

It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA.

Vaccination 52

Vaccination Vaccine DNA Protein 52

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. billion deal in 2018.

RNA 105

RNA Genetics Dermatology Antibody 105

XTalks

JUNE 18, 2024

This innovative technology, capable of carrying large protein payloads, has demonstrated potential in restoring muscular function in a mouse model of Duchenne muscular dystrophy (DMD) through the delivery of a full-length dystrophin protein.

Protein 52

Protein RNA Genetics Clinical Trials 52

Drug Discovery World

FEBRUARY 6, 2024

Scientific sessions Tuesday’s presentations spanned a range of topics, including functional genomics for target identification, next-generation proteomics, self-driving laboratories, the future of cell culture, and ‘lab on a particle’ technology.

Life Science 64

Life Science Genome Genomics RNA 64

Drug Discovery World

OCTOBER 5, 2023

The presentations will be followed by a panel discussion addressing new drug discovery and development concepts and tools in cancer research, and how these new approaches – e.g. engineered proteins, antibodies, micro RNA, nanocarriers, antibody drug conjugates – can help address unmet need in oncology. More to be announced.

Research 52

Research Antibody Medicine RNA 52

Drug Discovery World

NOVEMBER 15, 2022

The brainchild of multidisciplinary experts in computer science, physics, engineering, and biology, the field of synthetic biology has not only rapidly progressed in the last few decades but it’s also becoming more accessible and cost-effective. Synthetic libraries for antibody drug discovery .

DNA 98

DNA Drugs Antibody Engineer 98

Drug Discovery World

JANUARY 21, 2024

It is enabling computational protein design for vaccine immunogen discovery, and high-throughput and high-definition assays for quicker and more comprehensive characterisation of vaccine candidates and vaccine-elicited immunity. His recent research focuses on vaccines against influenza and other (re)emerging viruses.

Protein 52

Protein Vaccination Vaccine Development 52

Drug Discovery World

DECEMBER 15, 2022

Inducing double strand breaks at unintended locations in the genome can lead to off-target genetic modifications that are difficult to predict and potentially deleterious. Complicating matters even more, researchers currently lack effective and reliable methods for detecting and measuring off-target genomic events.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

XTalks

AUGUST 5, 2020

In recent webinars by Genuity Science, formerly known as WuXi NextCODE, experts from the biotech and pharma industries spoke about leveraging the power of single cell RNA sequencing platforms and solutions in conjunction with machine learning technologies such as AI in cell biology and disease research. The Power of Single Cell Technology.

Gene Expression 112

Gene Expression Development RNA Drugs 112

XTalks

MAY 4, 2021

The tool could also prove to be safer than conventional CRISPR-based gene therapies as it does not involve DNA editing, and thus would not cause potentially harmful off-target genomic changes. Epigenetic Editing with CRISPR. DNA methylation occurs endogenously in all mammalian cells in response to various stimuli.

DNA 98

DNA Gene Gene Silencing Genome 98

XTalks

DECEMBER 13, 2023

Related: Top 30 Pharma Companies in 2023: Statistics and Trends 1) Moderna Compound annual growth rate: 415 percent Moderna, headquartered in Massachusetts, is a prominent biotechnology company specializing in RNA therapeutics, particularly mRNA vaccines. Alpine Immune Sciences has recently announced an augmentation in its R&D investment.

Genetics 111

Genetics Vaccination Vaccine DNA 111

XTalks

NOVEMBER 30, 2023

Its mechanism of action involves blocking the protein shell (capsid) of the HIV-1 virus, disrupting multiple crucial stages of the viral lifecycle. Over 26 weeks of Sunlenca combined with other antiretroviral drugs, 81 percent of participants achieved HIV RNA suppression, reaching levels low enough to be considered undetectable.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Drug Discovery World

JANUARY 23, 2023

Increasing interest in CRISPR-Cas gene editing systems over recent years has delivered innovative developments in precision genome engineering technologies, holding enormous potential for applications across the healthcare sector. 2016/17 saw the emergence of this novel CRISPR-Cas9-based approach.

Gene Editing 52

Gene Editing Gene Engineer DNA 52

Drug Discovery World

AUGUST 10, 2022

Finally, in 2017, after years of improving T cell engineering techniques, the first chimeric antigen receptor (CAR) T cell therapy received FDA approval. To overcome this evasion tactic, the CAR protein was developed to recognise other markers on cancer cells. CAR T cells are T cells that have been trained to attack tumours.

Manufacturing 98

Manufacturing Gene Genome Genomics 98

Drug Discovery World

APRIL 6, 2023

These topics will be represented across a range of session types, including methods workshops, minisymposia, poster and plenary sessions, as well as keynotes, awards and lectures.

Protein 52

Protein Antibody Clinical Trials Clinical Trials 52

Drug Discovery World

JANUARY 3, 2023

protease or kinase inhibitors) or protein-protein interactions (e.g., Targeted protein degradation and related modalities. A new modality where DEL screening has had particular impact is targeted protein degradation (TPD), a modality that has generated rapidly increasing interest in recent years.

DNA 52

DNA Protein Drugs RNA 52

Drug Discovery World

MAY 30, 2023

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. At PhoreMost, we have been particularly excited about the emergence of targeted protein degradation (TPD) as a new therapeutic modality.

Research 52

Research Drugs Protein RNA 52

XTalks

MAY 4, 2021

The tool could also prove to be safer than conventional CRISPR-based gene therapies as it does not involve DNA editing, and thus would not cause potentially harmful off-target genomic changes. Epigenome Editing with CRISPR. DNA methylation occurs endogenously in all mammalian cells in response to various stimuli.

DNA 52

DNA Gene Gene Silencing Genome 52

XTalks

DECEMBER 24, 2020

From isolating SARS-CoV-2 in early January to sequencing its genome shortly thereafter and having a prototype vaccine against it within days, scientific process and progress have held steadfast throughout the pandemic. Most antibody drugs and vaccines have been developed to target parts of the spike protein. Innovations.

Life Science 111

Life Science Vaccination Vaccine Gene 111

Drug Discovery World

FEBRUARY 6, 2023

This approach has led to the development of two software packages for RNA sequencing analysis and reproducible ribosomal profiling 1,2. For example, we recently collaborated with two sequencing laboratories to determine optimal parameters for RNA-Sequencing (RNA-Seq) in the context of a vaccine clinical trial. F1000Research.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

Drug Discovery World

JUNE 6, 2023

I think they are still just at the cusp of really understanding how we use the molecular degrader and how we optimise them towards something that is clinically relevant, rather than a research tool which shows we can degrade the protein and understand the pharmacology but isn’t necessarily endowed with all the right properties to be a drug.

Protein 52

Protein DNA RNA Research 52

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. We also recently opened the Scientific Centre of Excellence for Genomic Insight at our Cambridge site.”

Drugs 75

Drugs Life Science Gene Therapy Genome 75

The Pharma Data

OCTOBER 19, 2020

By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through the Caris Molecular Intelligence® platform, physicians from Winship will be able to further prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients.

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52

Drug Discovery World

JULY 11, 2023

Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions.

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

OCTOBER 4, 2022

As it stands, there are currently 19 gene therapies approved for clinical use, alongside 18 RNA therapies and 59 non-genetically modified cell therapies, according to the Q2 report by the American Society of Cell & Gene Therapy. In the UK, effort has been made to scale-up the country’s cell and gene therapy manufacturing capabilities.

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. ImmunityBio’s platform is based on the foundation of three separate modalities: antibody cytokine fusion proteins, synthetic immunomodulators, and second-generation human adenovirus (hAd5) vaccine technologies.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

pharmaphorum

FEBRUARY 3, 2021

These treatments are examples of patient-specific, engineered chimeric antigen receptor (CAR)-T cell therapies that harness the immune system to target and eliminate cancer cells. Thus, the availability of universal, “off-the-shelf” engineered T cells presents an attractive alternative.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

Drug Discovery World

SEPTEMBER 6, 2022

The mysteries of cancer are starting to yield to the range of advanced therapies available and cell therapies – especially engineered cell therapies – are at the leading edge of that progress.” – Carlo Russo, CEO of Genenta.? . “In Research into genomic medicines is only at its infancy. New indications .

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52